IMMERVISION
23.11.2021 20:38:09 CET | Business Wire | Press release
Immervision, the world’s leading developer of advanced vision systems combining optics, image processing, and sensor fusion technology, today announced its ultra-wide lenses will be integrated into IONODES’ PERCEPT body camera. This collaboration will give businesses and the general public greater peace of mind, by providing physical security workers with a body camera that can effectively capture in real-time any potential security threats or issues in high resolution and never miss a detail through a Panomorph lens with 180° field of view.
“In the physical security industry, the challenge that most companies face with body worn cameras is that the video fails to effectively capture what’s occurring due to narrow field-of-view and poor image resolution,” said Eric Tasso, President at IONODES. “By selecting Immervision technology and their team of experts, we are providing security, industrial and commercial organizations with the highest-quality wearable cameras to improve safety, enhance security, optimize business processes and provide transparency."
IONODES’ body-worn IoT device is the first of a series of products that combines Immervision’s ultra-wide-angle lens, image processing and sensor technology with IONODES 4K camera, and connects to Wi-Fi, Bluetooth and LTE. IONODES’ device integrates seamlessly with a GPS receiver and 9-axis motion sensor, allowing users to closely follow the field of view in real-time, to stabilize the image and provide location tracking to users, whether for security, prevention, monitoring or entertainment applications
“Over the last 20 years, Immervision has focused on cultivating and perfecting its expertise in advanced vision systems, giving devices in industries such as physical security the ability to truly perceive the world around them,” said Pascale Nini, President and CEO at Immervision. “Immervision and IONODES are deeply committed to offering the best vision systems in the market for security and surveillance, and we look forward to continuing to make more innovative strides in developing high-quality wearable camera devices and AI-based vision systems.”
About Immervision
With over 20 years of innovation, Immervision creates solutions to see beyond human vision. To enable a machine to exceed human vision and unlock the full potential of AI, we develop advanced vision systems combining optics, image processing, and sensor fusion technology. Our Deep Seeing Technology enables hardware and software manufacturers to equip smart devices with the best vision possible for any industry including transportation, security, defense, computing, robotics, and more. www.immervision.com
About IONODES
IONODES is focused on pushing the boundaries of video technology, developing the latest in IP video storage, management and display solutions. Its experience in IP video and strong partnerships with industry leaders deliver innovative products designed to enhance people’s lifestyle while ensuring their safety and security.
IONODES designs, develops, and manufactures IP-based video solutions optimized for use in video surveillance. Its products include smart IP video appliances, such as body worn cameras, video encoders, video wall appliances, recording servers and workstations. The company offers its products through distributors, resellers, and representatives worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123006095/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom